Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.

Marina KonoplevaMichael J ThirmanKeith W PratzJacqueline S GarciaChristian RecherVinod PullarkatHagop M Kantarjian Courtney D D DiNardoMonique DailYinghui Duan Brenda J ChylaJalaja PotluriCatherine L Miller Andrew H Wei

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

When treated with venetoclax + azacitidine, patients with FLT3 mutations and FLT3 wild-type had similar outcomes. Future analyses in larger patient populations may further define the impact of venetoclax + azacitidine in patients harboring FLT3-ITD. See related commentary by Perl and Vyas, p. 2719.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
wild type
end stage renal disease
newly diagnosed
chronic lymphocytic leukemia
chronic kidney disease
ejection fraction
prognostic factors
case report
metabolic syndrome
patient reported outcomes
adipose tissue
weight loss